Takeda Mempersembahkan Data Terbaru dari Studi Fase 2b Mezagitamab, Menunjukkan Potensi untuk Mengubah Pengobatan Trombositopenia Imun Primer.

Takeda Mempersembahkan Data Terbaru dari Studi Fase 2b Mezagitamab, Menunjukkan Potensi untuk Mengubah Pengobatan Trombositopenia Imun Primer.

;accessed from this link are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be accompanied by words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will,” and other words and terms of similar meaning. Forward-looking